Xirtam 20 Tablet contains Olmesartan Medoxomil 20 mg, an angiotensin II receptor blocker (ARB) primarily indicated for the management of hypertension. By selectively inhibiting the binding of angiotensin II to the AT1 receptor, Xirtam 20 facilitates vasodilation, thereby reducing peripheral vascular resistance and lowering blood pressure. This mechanism helps prevent complications associated with hypertension, including stroke, myocardial infarction, and renal impairment. Xirtam 20 is typically administered once daily, with or without food, and dosage adjustments may be necessary based on patient response and renal function. It is contraindicated in patients with hypersensitivity to Olmesartan or any component of the formulation, and caution is advised in individuals with impaired renal or hepatic function. Common adverse effects may include dizziness, headache, and fatigue, while serious side effects are rare but may involve hyperkalemia or renal dysfunction. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Xirtam 20 should not be used during pregnancy due to potential fetal toxicity. This medication offers an effective option for blood pressure control, improving cardiovascular outcomes when used as part of a comprehensive treatment plan under medical supervision.